Patients with a favourable decline in human chorionic gonadotropin and alfa-fetoprotein continued BEP ( Fav-BEP group ) for @ additonal cycles , whereas patients with an unfavourable decline were randomly assigned ( @:@ ) to receive either BEP ( Unfav-BEP group ) or a dose-dense regimen ( Unfav-dose-dense group ) , consisting of intravenous paclitaxel ( @ mg/m ( @ ) over @ h on day @ ) before BEP plus intravenous oxaliplatin ( @ mg/m ( @ ) over @ h on day @ ; two cycles ) , followed by intravenous cisplatin ( @ mg/m ( @ ) over @ h on day @ ) , intravenous ifosfamide ( @ g/m ( @ ) over @ h on days @ , @ , and @ ) , plus mesna ( @ mg/m ( @ ) at @ , @ , @ and @ h ) , and bleomycin ( @ units per day , by continuous infusion for @ days on days @-@ ; two cycles ) , with granulocyte-colony stimulating factor ( lenograstim ) support .